CAMBRIDGE, Mass.--(BUSINESS WIRE)--Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced today positive results of the Phase 1 dosimetry trial of its lead oncology molecular radiotherapeutic candidate, AzedraTM (UltratraceTM iobenguane I 131, or Ultratrace MIBG) and further preclinical studies. The trial was designed to evaluate the safety, tolerability and distribution of Azedra in adult patients with either carcinoid or pheochromocytoma neuroendocrine cancers. Results from the trial were part of an oral presentation at the European Association of Nuclear Medicine 2007 Annual Congress in Copenhagen, Denmark. The presentation also highlighted that the ultrapurity resulting from Ultratrace technology used in Azedra produced no change in overall patient safety and that Azedra demonstrated increased efficacy and safety over currently available MIBG in preclinical animal models.
